0
Abstract: Slide Presentations |

THE USE OF SILDENAFIL IN THE ACUTE TREATMENT OF PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION AND RIGHT HEART FAILURE FREE TO VIEW

Lalaine M. Corate, MD*; Patricio Escalante, MD; Glenna Traiger, MSN; Wendy Hill, MSN; Rory Hachomavich, MD; Shelley Shapiro, MD
Author and Funding Information

University of Southern California, Los Angeles, CA


Chest


Chest. 2005;128(4_MeetingAbstracts):174S. doi:10.1378/chest.128.4_MeetingAbstracts.174S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  The acute treatment of severe Pulmonary Arterial Hypertension (PAH) poses a therapeutic challenge. Immediate access to agents such as prostacyclin and endothelin receptor blockers (ERBs) is limited. Sildenafil has been shown to have a direct vasodilator effect in the pulmonary circulation. The goal of this study is to describe the treatment response to Sildenafil for unstable, WHO Class IV PAH patients.

METHODS:  We performed a retrospective, cohort review of 14 consecutive patients with WHO Class IV PAH admitted to the hospital in severe right heart failure (RHF) and treated with Sildenafil. Treatment also included digoxin, diuretics and inhaled nitric oxide. Sildenafil was initiated at 50 mg TID and increased to 100 mg TID after 24 hours. Outpatient follow-up data and outcome measurements included periodic 6-minute walks (6MW), supplemental oxygen requirements, WHO classification status, need for additional PAH therapy, hospitalizations and death.

RESULTS:  All patients were discharged on Sildenafil without concomitant prostacyclin or ERBs. After ≥ 4 weeks of therapy with Sildenafil, the mean increase in 6MW (compared to pre-discharge 6MW) was 122.4 meters (95%CI:50.5-194.3, p=0.004). The mean reduction in oxygen supplementation by nasal cannula was 2.1L (95%CI:3.53-0.75, p=0.005). The degree of improvement in 6MW distance, oxygen requirements, and WHO classification status was statistically associated with the time of treatment on Sildenafil. At 6 months, the average 6MW distance was 351M (n=5). Four patients had additional therapy added ≥ 5 months. One patient died and 3 patients required re-hospitalization prior to 1 year for progressive PAH and RHF. At 1 year, 13 patients remained on Sildenafil and were WHO Class II-III, without signs of RHF. No significant side effects were noted.

CONCLUSION:  Sildenafil 100 mg TID can be used in the acute setting to stabilize patients with WHO Class IV PAH. Long-term therapy with Sildenafil was associated with good clinical outcomes, including improvement in WHO classification and 6MW distance.

CLINICAL IMPLICATIONS:  This study proposes a treatment strategy for decompensated PAH that circumvents problems of delayed access to prostacyclins and ERBs therapy.

DISCLOSURE:  Lalaine Corate, None.

Tuesday, November 1, 2005

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543